Mini Review-The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers

Hormone Molecular Biology and Clinical Investigation

Volumn 1, Issue 3, 2010, Pages 103-110

  Szepeshazi, Karoly ^a,b   Block, Norman L ^a,b   Schally, Andrew V ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

gastrointestinal cancer; liver cancer; pancreatic cancer; peptide hormones; urinary bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BOMBESIN; GASTRIN RELEASING PEPTIDE; GONADORELIN; GROWTH HORMONE RELEASING FACTOR; HORMONE ANALOG; HYPOTHALAMUS HORMONE; PEPTIDE DERIVATIVE; PEPTIDE HORMONE; SOMATOSTATIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR GROWTH;

EID: 84865983293     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.018     Document Type: Article

References (40)

1. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008;40:1-8.
2. Schally AV., Szepeshazi K., Nagy A., Comaru-Schally AM., Halmos G. New approaches to therapy of cancers of the stomach., colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004;61:1042-68.
3. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
4. Krenning EP., Kwekkeboom DJ., Bakker WH., Breeman WAP., Kooij PPM., Oei HY., van Hagen M., Postema PTE., de Jong M., Reubi JC., Visser TJ., Reijs AEM., Hofland LJ., Koper JW., Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
5. Schally AV., Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15: 300-10.
6. Nagy A., Schally AV. Targeting cytotoxic conjugates of somatostatin., luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a smarter chemotherapy. Curr Pharmacol Design 2004;14:1167-80.
7. Jensen RT., Battey JF., Spindel ER., Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature., distribution., pharmacology., signaling and functions in normal and disease states. Pharmacol Rev 2008;60: 1-42.
8. Weber CH. Regulation and signaling of human bombesin receptors and their biological effects. Curr Opin Endocrinol Diabetes Obes 2009;16:66-71.
9. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49: 318-26.
10. Schally AV., Engel J. Analogs of luteinizing hormone-releasing hormone (LHRH) in cancer. In: Kastin A., editor. Handbook of biologically active peptides. Amsterdam: Elsevier., 2006:421-7.
11. Kovacs M., Szepeshazi K., Schally AV. Endocrine and antineo-plastic effects of antagonistic and cytotoxic analogs of luteinis-ing hormone-releasing hormone. In: Kovacs M., Merchenthaler I., editors. Neuropeptides and peptide analogs. Kerala., India: Research Signpost., 2009;37:1-25.
12. Debruyne F., Gres AA., Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign pro-static hyperplasia. Eur Urol 2008;54:170-80.
13. Boyle P., Levin B., editors. World cancer report 2008. Lyon: International Agency for Research on Cancer., WHO Press., 2008.
14. Jemal A., Thun MJ., Ries LAG., Howe HL., Weir HK., Center MM., Ward E., Wu XC., Eheman C., Anderson R., Ajani UA., Kohler B., Edwards BK. Annual report to the nation on the status of cancer., 1975-2005, featuring trends in lung cancer., tobacco use., and tobacco control. J Natl Cancer Inst 2008;100:1672-94.
15. Thomas RP., Hellmich MR., Townsend CM Jr., Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003;24:571-99.
16. Szepeshazi K., Schally AV., Nagy A., Wagner BW., Bajo AM., Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003;98:1401-10.
17. Min Y., Adachi Y., Yamamoto H., Imsumran A., Arimura Y., Endo T., Hinoda Y., Lee C-T., Nadaf S., Carbone DP., Imai K. Insulinlike growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005;54:591-600.
18. American Cancer Society. Cancer facts & figures 2009. Atlanta., GA: American Cancer Society., 2009.
19. Szepeshazi K., Schally AV., Groot K., Armatis P., Halmos G., Hebert F., Szende B., Varga JL., Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000; 82:1724-31.
20. Busto R., Schally AV., Varga JL., Garcia-Fernandez MO., Groot K., Armatis P., Szepeshazi K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 2002;99:11866-71.
21. Szepeshazi K., Schally AV., Halmos G., Armatis P., Hebert F., Sun B., Feil A., Kiaris H., Nagy A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor positive exper imental colon cancers independently of their p53 status. Cancer Res 2002;62:781-8.
22. Szepeshazi K., Schally AV., Halmos G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 2007;30:1485-92.
23. Szepeshazi K., Halmos G., Schally AV., Arencibia JM., Groot K., Vadillo-Buenfil M., Rodriguez-Martin E. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. J Cancer Res Clin Oncol 1999;125:444-52.
24. Bajo AM., Schally AV., Groot K., Szepeshazi K. Bombesin antagonist inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004;90:245-52.
25. Szepeshazi K., Schally AV., Halmos G., Sun B., Hebert F., Csernus B., Nagy A. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin Cancer Res 2001;7:2854-61.
26. Mimeault M., Brand RE., Sasson AA., Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005;31:301-16.
27. El Fitori J., Su Y., Büchler MW., Quentmeier H., Hines OJ., Herr I., Friess H. PKC412 small-molecule tyrosine kinase inhibitor. Single compound therapy for pancreatic cancer. Cancer 2007; 110:1457-68.
28. Szepeshazi K., Schally AV., Groot K., Armatis P., Hebert F., Hal-mos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer 2000;36:128-36.
29. Szepeshazi K., Schally AV., Nagy A., Halmos G. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Pancreas 2005;31:275-82.
30. Faivre S., Dreyer C., El Maalouf G., Sablin M-P., Raymond E. Rationale for targeted therapies in hepatocellular carcinoma. Target Oncol 2008;3:81-5.
31. Thorgeirsson SS., Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
32. Chiang DY., Villanueva A., Hoshida Y., Peix J., Newell P., Min-guez B., LeBlanc AC., Donovan DJ., Thung SN., Sole M., Tovar V., Alsinet C., Ramos AH., Barretina J., Roayaie S., Schwartz M., Waxman S., Bruix J., Mazzaferro V., Ligon AH., Najfeld V., Friedman SL., Sellers WR., Meyerson M., Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
33. Giannitrapani L., Soresi M., La Spada E., Cervello M., D'Ales-sandro N., Montalto G. Sex hormones and risk of liver tumor. Ann NY Acad Sci 2006;1089:228-36.
34. Di Maio M., Daniele B., Pignata S., Gallo C., De Maio E., Mora-bito A., Piccirillo MC., Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol 2008;14:1682-9.
35. Reubi JC., Zimmermann A., Jonas S., Waser B., Läderach U., Wie-denmann B. Regulatory peptide receptors in human hepatocel-lular carcinomas. Gut 1999;45:766-74.
36. Szepeshazi K., Schally AV., Treszl A., Seitz S., Halmos G. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone., somatostatin or bombesin. Anti-Cancer Drugs 2008;19:349-58.
37. Babjuk M., Oostrlinck W., Sylvester R., Kaasinen E., Böhle A., Palou-Redorta J. EAU guidelines on non-muscle-invasive uro-thelial carcinoma of the bladder. Eur Urol 2008;54:303-14.
38. Belmunt J., Albiol S., Suarez C., Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hemat 2009;69:211-22.
39. Bahk JY., Kim MO., Park MS., Lee HY., Lee JH., Chung BC., Min SK. Gonadotropin-releasing hormone (GnRH) and GnRH recep tor in bladder cancer epithelia and GnRH effect on bladder cancer proliferation. Urol Int 2008;80:431-8.
40. Fleischmann A., Waser B., Reubi JC. High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications. Endocr Relat Cancer 2009;16:623-33.